Skip to main content

Table 2 Comparison of treatments in the gemcitabine-only and cisplatin-gemcitabine group

From: Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study

  Group 1 (n = 9, GEM) Group 2 (n = 21, CIS/GEM)
Time of initiation days; median (IQR) 48 (38.5–56.5) 54 (39.5–70.5)
Number of courses; median 6 8/8
Completion rate; % 98% 81%/88%
Dose reduction; no. 7 15
  1. Abbreviations: GEM gemcitabine, CIS cisplatin, IQR interquartile range